Corbus Pharmaceuticals
NASDAQ: CRBPNew York, US · Founded 2013 · 1 known investors
Find your way into Corbus Pharmaceuticals
Sign up to see every warm intro you have to Corbus Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Corbus Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Corbus Pharmaceuticals is a biopharmaceutical company developing therapies for critical stages of clinical development, with a focus on advancing patient-centered progress in drug development. The company is led by a senior leadership team with expertise in pharmaceutical research, regulatory affairs, and clinical development.
Founders & leadership
Corbus Pharmaceuticals was founded in 2013 by Yuval Cohen.

Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$6.4M disclosed across 3 of 4 rounds · 1900–2014
▶$6.3MraisedApr 2014 · 45 investors · InvestingRule 506(b)
- Robert ZurierExecutive Officer
- Yuval CohenExecutive Officer, Director
- Alan HolmerDirector
- Sean MoranExecutive Officer
- David HochmanDirector
- Mark TepperExecutive Officer
- Offering amount
- $13M
- Amount sold
- $6.3M
- Sales commissions
- $1.3M
- Placement agents
- Aegis Capital Corp.
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$19.8KraisedMar 2014 · 3 investors · InvestingRule 506(b)
- John BrancaccioExecutive Officer
- David HochmanExecutive Officer, Director
- Offering amount
- $30K
- Amount sold
- $19.8K
- First sale
- Mar 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$90KraisedJan 2014 · 19 investors · InvestingRule 506(b)
- David HochmanExecutive Officer, Director
- John BrancaccioExecutive Officer
- Offering amount
- $90K
- Amount sold
- $90K
- First sale
- Dec 2013
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
3 people who came through Corbus Pharmaceuticals went on to found or lead other companies.
Related companies · 8
Companies working in the same space as Corbus Pharmaceuticals.
Frequently asked questions
- What does Corbus Pharmaceuticals do?
- Corbus Pharmaceuticals is a biopharmaceutical company developing therapies for critical stages of clinical development, with a focus on advancing patient-centered progress in drug development. The company is led by a senior leadership team with expertise in pharmaceutical research, regulatory affairs, and clinical development.
- Who founded Corbus Pharmaceuticals?
- Corbus Pharmaceuticals was founded by Yuval Cohen in 2013.
- Who are Corbus Pharmaceuticals's investors?
- Corbus Pharmaceuticals's investors include Boston Harbor Angels.
- How much funding has Corbus Pharmaceuticals raised?
- Corbus Pharmaceuticals has disclosed $6.4M raised across 3 of its 4 known rounds.
- Where is Corbus Pharmaceuticals headquartered?
- Corbus Pharmaceuticals is headquartered in New York, US.







